<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609748</url>
  </required_header>
  <id_info>
    <org_study_id>KB-0012/149/2020</org_study_id>
    <nct_id>NCT04609748</nct_id>
  </id_info>
  <brief_title>Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.</brief_title>
  <official_title>Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pomeranian Medical University Szczecin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pomeranian Medical University Szczecin</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the study, the effectiveness of analgesic therapy with nimmsulide and cannabidiol oil&#xD;
      will be compared.&#xD;
&#xD;
      Two study groups will be formed. The study will be conducted on patients reporting to the&#xD;
      Dental Prosthetics Clinic of PUM in Szczecin. Patients aged 18-65 years with pain located in&#xD;
      the area of the temporomandibular joint and the preauricular area, resulting from a&#xD;
      dysfunction of the temporomandibular joint, will be included in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>15 days</time_frame>
    <description>Measured on Visual Analogue Scale (VAS) scale. It consists of a line, approximately 100mm in length, at the left end of the scale &quot;Score 0&quot; which means &quot;no pain&quot;, at the right end of the scale &quot;Score 100mm&quot; which means &quot;worst imaginable pain&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychological conditions</measure>
    <time_frame>15 days</time_frame>
    <description>Measured on The General Health Questionnaire-28 (GHQ-28)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Temporomandibular Joint Disorders</condition>
  <condition>Temporomandibular Joint Dysfunction Syndrome</condition>
  <condition>Temporomandibular Joint Pain</condition>
  <arm_group>
    <arm_group_label>The group that received nimesulide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>The group that received CBD Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol Oil</intervention_name>
    <description>Cannabidiol oil will be given twice a day, in a dose of 33,6mg, applied orally. The therapy will last 15 days.</description>
    <arm_group_label>The group that received CBD Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimesulide</intervention_name>
    <description>Nimessulid will be given twice a day - 2x100mg, applied orally. The therapy will last 15 days.</description>
    <arm_group_label>The group that received nimesulide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients (female and male) aged 18-65 years, able to swallow tablets&#xD;
&#xD;
          2. Patients with pain located in the temporomandibular and preauricular regions resulting&#xD;
             from temporomandibular joint dysfunction&#xD;
&#xD;
          3. Patients with clinical diagnosis of Temporomandibular Joint Dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with clinically diagnosed acute inflammation of the outer ear, middle ear,&#xD;
             sinuses of the nose&#xD;
&#xD;
          2. patients allergic to nimesulide or cannabidiol oil&#xD;
&#xD;
          3. patients with contraindications to include therapy with nimesulide or cannabidiol oil&#xD;
             such as:&#xD;
&#xD;
               -  gastric or duodenal ulcer disease,&#xD;
&#xD;
               -  severe blood clotting disorders,&#xD;
&#xD;
               -  severe liver dysfunction,&#xD;
&#xD;
               -  severe renal impairment,&#xD;
&#xD;
               -  severe heart failure, pregnancy,&#xD;
&#xD;
               -  breastfeeding,&#xD;
&#xD;
               -  concomitant intake of citrochrome blockers CYP3A4 or CYPP2D6 (warfarin,&#xD;
                  macrolides, calcium channel blockers, benzodiazepines, cyclosporine, sildenafil,&#xD;
                  SSRI, tricyclic antidepressants, opioids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bartosz Dalewski, DMD, PhD</last_name>
    <phone>914661717</phone>
    <email>bartosz.dalewski@pum.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kamila Szczuchniak, DMD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chair and Depratment of Dental Prosthetics</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartosz Dalewski, DMD, PhD</last_name>
      <email>bartosz.dalewski@pum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Kamila Szczuchniak, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pomeranian Medical University Szczecin</investigator_affiliation>
    <investigator_full_name>Dalewski Bartosz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>temporomandibular joint</keyword>
  <keyword>CBD oil</keyword>
  <keyword>non steroid antyinflammatory drug</keyword>
  <keyword>nimesulide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimesulide</mesh_term>
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

